Mitochondria-targeting aromatic-cationic tetrapeptide; generic name elamipretide
PRODUCT PROFILE
SS-31 (Elamipretide)
£29.99
SS-31 (Elamipretide) is mitochondria-targeting aromatic-cationic tetrapeptide; generic name elamipretide. Researchers examine it in relation to cardiolipin, oxidative phosphorylation and mitochondrial-disease outcomes.
Why it is distinct
Directly targets mitochondrial membrane cardiolipin, unlike MOTS-c’s signalling-peptide role.
- Evidence stageClinical research
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
SS-31 (Elamipretide) is mitochondria-targeting aromatic-cationic tetrapeptide; generic name elamipretide. Researchers examine it in relation to cardiolipin, oxidative phosphorylation and mitochondrial-disease outcomes.
Research focus+
Researchers study whether it can protect mitochondrial membranes and improve how cells make energy. Human trials exist, but benefits vary by condition and it remains investigational in many settings.
How the mechanism differs+
Concentrates at the inner mitochondrial membrane and interacts with cardiolipin to influence electron transport and membrane stability.
Evidence and limitations+
Multiple human trials exist, including mixed or unmet primary endpoints; development remains condition-specific.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether it can protect mitochondrial membranes and improve how cells make energy. Human trials exist, but benefits vary by condition and it remains investigational in many settings.
Concentrates at the inner mitochondrial membrane and interacts with cardiolipin to influence electron transport and membrane stability.
Directly targets mitochondrial membrane cardiolipin, unlike MOTS-c’s signalling-peptide role.
Multiple human trials exist, including mixed or unmet primary endpoints; development remains condition-specific.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Phase 2 clinical research
MOTS-c
£35.64Batch file pendingMOTS-c begins inside mitochondria and is studied for cell-wide energy adaptation, rather than directly targeting appetite receptors.
Available · 30 in stockAdd to basket -
Preclinical
BPC-157
£32.99Batch file pendingBPC-157 is mainly discussed around stomach and local tissue-repair models. TB-500 is instead studied for actin, cell movement…
Available · 30 in stockAdd to basket -
Phase 2 clinical research
GHK-Cu
£24.99Batch file pendingGHK-Cu is a copper complex. Pal-GHK has a fatty tail for topical formulas, while non-copper peptides use different…
Available · 50 in stockAdd to basket -
Preclinical
Humanin
£68.0010 mgBatch file pendingPrimarily cytoprotective/anti-apoptotic, whereas MOTS-c centres on metabolic stress signalling.
UnavailableAsk about availability